Skip to main content

Table 2 Correlation of MYC and BCL2 expression and clinicopathological variables

From: MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system

  

MYC, n (%)

BCL2, n (%)

Variablesa

 

<40

≥40

P

<30

≥30

P

Age (yr)

mean ± SD

57.6 ± 14.6

63.1 ± 7.6

0.097

50.4 ± 19

61.3 ± 10.4

<0.001

Age (yr)

≤50

22 (95.7)

1 (4.3)

0.069

11 (47.8)

12 (52.2)

0.004

>50

71 (78)

20 (22)

17 (18.7)

74 (81.3)

Age (yr)

≤60

46 (83.6)

9 (16.4)

0.584

18 (32.7)

37 (67.3)

0.051

>60

47 (79.7)

12 (20.3)

10 (16.9)

49 (83.1)

Sex

M

55 (84.6)

10 (15.4)

0.335

20 (30.8)

45 (69.2)

0.076

F

38 (77.6)

11 (22.4)

8 (16.3)

41 (83.7)

ECOG PS

0, 1

62 (84.9)

11 (15.1)

0.172

19 (26)

54 (74)

0.731

2–4

29 (74.4)

10 (25.6)

9 (23.1)

30 (76.9)

KPS

≥70

81 (83.5)

16 (16.5)

0.136

24 (24.7)

73 (75.3)

>0.999

<70

9 (64.3)

5 (35.7)

3 (21.4)

11 (78.6)

B symptoms

Absent

88 (80.7)

21 (19.3)

0.582b

26 (23.9)

83 (76.1)

0.595b

Present

5 (100)

0 (0)

2 (40)

3 (60)

Serum LDH

Normal

54 (79.4)

14 (20.6)

0.506

19 (27.9)

49 (72.1)

0.582

Elevated

33 (84.6)

6 (15.4)

9 (23.1)

30 (76.9)

Cell of origin

GCB

22 (91.7)

2 (8.3)

0.236b

11 (45.8)

13 (54.2)

0.005

Non-GCB

70 (78.7)

19 (21.3)

16 (18)

73 (82)

Involvement of deep structure

Absent

24 (80)

6 (20)

0.795

6 (20)

24 (80)

0.499

Present

69 (82.1)

15 (17.9)

22 (26.2)

62 (73.8)

Extent of disease

Unifocal

34 (81)

8 (19)

0.895

11 (26.2)

31 (73.8)

0.758

Multifocal

59 (81.9)

13 (18.1)

17 (23.6)

55 (76.4)

Ocular involvement

Absent

82 (81.2)

19 (18.8)

>0.999b

25 (24.8)

76 (75.2)

>0.999b

Present

10 (83.3)

2 (16.7)

3 (25)

9 (75)

CSF protein

Normal

31 (79.5)

8 (20.5)

0.844

8 (20.5)

31 (79.5)

0.157

Elevated

43 (81.1)

10 (18.9)

18 (34.0)

35 (66.0)

CSF cytology

Negative

66 (80.5)

16 (19.5)

>0.999b

19 (23.2)

63 (76.8)

0.121

Positive

11 (78.6)

3 (21.4)

6 (42.9)

8 (57.1)

IELSG

0–2

35 (81.4)

8 (18.6)

0.790

13 (30.2)

30 (69.8)

0.740

3–5

38 (79.2)

10 (20.8)

13 (27.1)

35 (72.9)

Nottingham- Barcelona

0–1

46 (86.8)

7(13.2)

0.154

16 (30.2)

37 (69.8)

0.229

2–3

45 (76.3)

14 (23.7)

12 (20.3)

47(79.7)

MSKCC class

1

21 (100)

0 (0)

0.012b

10 (47.6)

11 (52.4)

0.008

2–3

70 (76.9)

21 (23.1)

18 (19.8)

73 (80.2)

  1. Abbreviations: ECOG PS The Eastern Cooperative Oncology Group performance score, KPS Karnofsky performance status score, LDH lactate dehydrogenase, GCB germinal center B cell-like, CSF cerebrospinal fluid, IELSG the International Extranodal Lymphoma Study group, MSKCC Memorial Sloan Kettering Cancer Center
  2. aSome cases have missing values that lacked the information about the variables
  3. bFisher’s exact test
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us